dc.contributor.authors |
Sengul, Aysun; Mutlu, Pinar; Ozdemir, Ozer; Satici, Celal; Turan, Muzaffer Onur; Arslan, Sertac; Ogang, Nalan; Unsal, Zuhal Ekici; Bozkus, Fulsen; Capraz, Aylin; Demirkol, Mustafa Asim; Mutlu, Levent Cern; Gulhanm, Pinar Yildiz; Alkilinc, Ersin; Fazlioglu, Nevin; Soyler, Yasemin; Kabalak, Pinar Akin; Kizilgoz, Derya; Turan, Pakize Ayse; Yildirim, Fatma; Aydemir, Yusuf; Sen, Nazan; Mirici, Arzu |
|
dc.date.accessioned |
2022-12-20T13:25:39Z |
|
dc.date.available |
2022-12-20T13:25:39Z |
|
dc.date.issued |
2022 |
|
dc.identifier.issn |
1747-6348 |
|
dc.identifier.uri |
http://dx.doi.org/10.1080/17476348.2022.2102480 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/99405 |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
Background COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia. |
|
dc.language |
English |
|
dc.language.iso |
eng |
|
dc.relation.isversionof |
10.1080/17476348.2022.2102480 |
|
dc.subject |
Respiratory System |
|
dc.subject |
COVID-19 |
|
dc.subject |
corticosteroid |
|
dc.subject |
hypoxemia |
|
dc.subject |
mortality |
|
dc.subject |
prognosis |
|
dc.title |
Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors |
|
dc.contributor.authorID |
Söyler, Yasemin/0000-0002-0507-0767 |
|
dc.contributor.authorID |
satici, celal/0000-0002-5457-9551 |
|
dc.identifier.volume |
16 |
|
dc.identifier.startpage |
953 |
|
dc.identifier.endpage |
958 |
|
dc.relation.journal |
EXPERT REVIEW OF RESPIRATORY MEDICINE |
|
dc.identifier.issue |
8 |
|
dc.identifier.doi |
10.1080/17476348.2022.2102480 |
|
dc.identifier.eissn |
1747-6356 |
|
dc.contributor.author |
Sengul, Aysun |
|
dc.contributor.author |
Mutlu, Pinar |
|
dc.contributor.author |
Ozdemir, Ozer |
|
dc.contributor.author |
Satici, Celal |
|
dc.contributor.author |
Turan, Muzaffer Onur |
|
dc.contributor.author |
Arslan, Sertac |
|
dc.contributor.author |
Ogang, Nalan |
|
dc.contributor.author |
Unsal, Zuhal Ekici |
|
dc.contributor.author |
Bozkus, Fulsen |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|